monosov_lab retweeted
Super happy to announce that we have got an Oral at #NeurIPS! 🥳
Together with amazing @ben_eysenbach, Peter Dayan, & @cpilab, we proposed a notion of controllability to derive bounds linking unsupervised skill learning to downstream goal-reaching.
arxiv.org/abs/2605.06145
1/8
monosov_lab retweeted
Excited to share our new preprint:
Parametric neural control differentiates top neural network models of primate visual cortex
biorxiv.org/content/10.64898…
with an amazing team: @WangBinxu *, @thomas_fel_ , @akjags , @grez72, @talia_konkle , Parisa Vaziri, and the Livingstone Lab at HMS.
@KempnerInst, @PsychHarvard, @harvardmed (2/14)
monosov_lab retweeted
💔May their memories be a blessing. May those who were injured heal completely. May light and love overcome darkness and hate. Am Yisrael Chai.
monosov_lab retweeted
This is a true tour de force by @panos_roussos and colleagues in the PsychAD Consortium. mountsinai.org/about/newsroo…
Research led by @MountSinaiNYC, featured in landmark collection of 9 papers, represents one of largest & most comprehensive applications of single-cell genomics to human brain disease research. Learn More 👉 mountsinai.org/about/newsroo…
monosov_lab retweeted
Mark your calendars! 📍 The 2026 Technology in Psychiatry Summit is back in Boston on Dec 10-11.
Whether you want to present your latest research or join the conversation, registration & submissions are now open. ✨ #TIPS2026 #digitalhealth
techinpsych.org
monosov_lab retweeted
Chief Scientific Officer Search at the AOI
The Ackman Oxman Institute (AOI) is a new translational neuroscience, rehabilitation, and brain health institute in New York City founded to accelerate the translation of promising science to treating and curing patients.
We are seeking a Chief Scientific Officer (CSO) who shares our ambition and recognizes that transformative advances depend on creative, independent scientists pursuing fundamental questions relevant to brain injury, degeneration, recovery, and rehabilitation.
The CSO will help shape AOI's scientific identity, organization, and culture. We welcome the candidate's ideas about how best to organize the science and create an environment in which outstanding investigators can do their best work.
Mandate
Lead AOI's discovery science enterprise. Working with the Chief Translational Officer (CTO) and institute leadership, the CSO will define the research agenda, recruit and develop exceptional scientists, and determine the mix of investigator-led laboratories, collaborative teams, shared resources, and external partnerships best suited to the mission. The portfolio will support two complementary kinds of work:
Patient-Anchored Translational Programs
Research developed in anticipation of, as well as in response to, clinical observations. For example, a mechanistic program on mitochondrial delivery and bioenergetic rescue could inform a parallel clinical study of mitochondrial transplantation. Programs pursuing a defined path to patients will have clear milestones and criteria for advancement, redirection, or stopping, appropriate to their stage of development.
Mission-Relevant Discovery Science
Protected support for fundamental research on brain injury, repair, plasticity, and aging, led by investigators with intellectual independence. Major continuation or stop decisions will use a five-to-seven-year horizon, with ongoing scientific exchange and peer review to maintain rigor. This work can generate new therapeutic ideas and give AOI the depth to recognize and pursue discoveries arising from patient studies.
The CSO will shape the balance between these forms of research and how they interact, with resources and review practices suited to each. Scientists will have the freedom to pursue original ideas within AOI's mission and contribute to a collaborative scientific community.
Scope and Responsibilities
Scientific Portfolio
Define the research agenda with the CTO across acquired brain injury (stroke, TBI), and neurodegenerative and neuropsychiatric diagnoses as well brain health in aging. Build on AOI's initial priorities in bioenergetics/mitochondria, neuroinflammation, and neuroplastogens (devices or biologics that increase neuroplasticity), helping refine their scope, sequence, and organization. Identify promising mechanistic programs early so AOI is prepared to act on clinical discoveries, and welcome new ideas through a transparent scientific review process.
Independent Discovery
Recruit exceptional investigators and give them the resources and latitude to pursue fundamental questions relevant to AOI's mission. Develop peer review that evaluates scientific quality, originality, and contribution over an appropriate time horizon, recognizes the value of well-reasoned negative results, and protects intellectual independence.
Scientific Infrastructure
Determine which laboratory and measurement capabilities will best support the science, and which to build internally, share, or access through partnerships. Guide scientific use of shared resources, including GLP vivarium and GMP capabilities, in coordination with the CTO and Chief Regulatory Officer.
Scientific Recruitment and Community
Shape a recruitment and support model that attracts outstanding scientists with diverse approaches to discovery and collaboration. Explore joint or affiliated academic appointments and shared recruitment with New York City and regional universities and medical centers, where these strengthen recruitment, mentorship, and scientific exchange. Appointment arrangements will be developed with partner institutions and individual recruits.
External Scientific Network
Build a network of well-funded collaborations with academic laboratories in New York City and the region whose fundamental work is relevant to AOI's mission, so that AOI's discovery capacity extends well beyond its own walls. The Pershing Square MIND Prize community is a natural springboard for this network, though collaboration is not limited to prize recipients. Work with the founders on how the MIND Prize and AOI's basic research program should relate to each other over time.
Scientific Quality
Lead a collegial, rigorous scientific review process. For translational and later-stage preclinical programs, agree on clear milestones and advancement or stop criteria with program leaders and the CTO. For fundamental discovery, combine ongoing scientific dialogue with substantive peer review and five-to-seven-year continuation decisions. Uphold research integrity and reproducibility across all programs.
External Standing
Represent AOI's science to the field, to funders (NIH, ARPA-H, DoD, philanthropy), to scientific advisors, and to academic and industry partners.
Relationship to the Chief Translational Officer
The CSO and CTO are peers who connect discovery with development and clinical investigation. The CSO leads fundamental and exploratory preclinical research; the CTO leads regulated preclinical development, manufacturing, engineering, and trial readiness, and clinical studies. They jointly define the evidence needed to advance a program into development and review the portfolio together. Scientific collaboration continues as programs advance and clinical observations raise new research questions.
First 6 Months
•Develop a scientific strategy with the CEO, CTO, and board, including the proposed research organization, the balance of discovery and translation, initial priorities and resources, and a first set of anticipatory mechanistic programs. Agree on review practices that protect independent discovery and support timely development decisions.
•Begin recruiting priority scientific leaders and independent investigators, with the mix and sequence of appointments shaped by the scientific strategy. Develop the support and affiliation arrangements needed to attract exceptional candidates.
•Establish an agreed plan for laboratory capabilities and launch initial research using in-house resources or external partnerships as appropriate. Work with the CTO and clinical leadership to align research with patient studies and their readiness requirements.
•Co-define the criteria for entering development with the CTO and begin well-funded collaborations with regional academic laboratories. Set the subsequent launch timetable around scientific priorities, recruitment, and facility readiness.
Who We Are Looking For
Essential
•MD/PhD or PhD with a first-rank research record in neuroscience, immunology/neuroinflammation, bioenergetics, or a convergent field.
•Experience building and leading a research organization (institute, department, biotech R&D unit, or focused research organization).
•A track record of attracting outstanding scientists.
•Enthusiasm for a patient-centered research model and for leading a team whose work spans the continuum from discovery to therapy development.
Valued
•Experience supporting independent investigators and collaborative research in academia, research institutes, or industry.
•Scientific credibility in at least one of AOI's initial priority areas.
•Comfort spanning biologics and device/neurotechnology science.
•A demonstrated ability to protect creative discovery while guiding translational programs toward clear milestones.
Practical
AOI welcomes candidates from academia and industry who are excited to build the institute over the coming decade and beyond. The position is full-time in New York City. Candidates should be eager to focus their research leadership on the brain, recovery, and rehabilitation; any continuing research commitments should support that mission. Compensation will be competitive and will include the opportunity to participate in the value created through company formation at AOI.
Leadership Team Engagement
Works closely with the CTO as described above and with clinical leadership to connect research and patient studies. Engages the legal/regulatory team early on regulatory strategy, quality systems, and evidence requirements. Collaborates with the Chief AI Officer on data-rich study design and computational modeling, the COO on laboratory development and recruitment operations, and the CFO on scientific resource planning.
Interested candidates should send their CV and a brief cover note to:
[email protected]
monosov_lab retweeted
First study out! Using a new cooperative paradigm and multi-agent inverse RL, we show that mice spontaneously adopt leader/follower roles, and the prefrontal cortex encodes these role dynamics and an egocentric social value map of the partner’s position.
nature.com/articles/s41586-0…
monosov_lab retweeted
Your academic CV is NOT linked to your ability to make big discoveries.
1. Andre Geim, a co-discoverer of graphene, wrote in his Nobel Lecture article:
“So, at the age of 33 and with an h index of 1 (latest papers not yet published), I entered the Western job market for postdocs.”
2. Albert Einstein searched for a teaching position for two years. He had to accept a position at a Patent Office, where in a SINGLE year he wrote FOUR papers that completely revolutionized science (the photoelectric effect, Brownian motion, special relativity, and E=mc2).
Only few years later did he finally enter academia, becoming a lecturer at the University of Bern. Not even a professor.
3. Katalin Karikó...
Her mRNA grant proposals were repeatedly rejected. She was demoted out of the faculty position to a senior research investigator. She remained in a low-status research position for 10 years. She had little grant funding and no independent laboratory. And yet she persisted with her ideas about modified RNA, eventually discovering how it could suppress inflammation and receiving the 2023 Nobel Prize (with Drew Weissman). It was a very hard path.
Other examples include Frances Arnold, Michael Brown, Randy Schekman, who got Nobel Prizes for the discoveries they made as young PIs in newly established labs. And many others.
📍So, let’s keep in mind that:
1. Big discoveries are often unforeseen. They emerge from wild hypotheses, random research and risky projects (e.g. graphene was a tiny side project!). Make sure you have such projects in your lab.
2. Most truly impactful discoveries did not require high h-indices, excessive funding or a high-IF journal. They required CREATIVE people and persistence.
3. Rejection of your proposal does NOT mean it proposes bad science. Such rejections represent the opinion of one person who has a rather subjective idea of what ‘good science’ means.
4. For younger people, it’s easier to do risky research. If we lock them to unnecessarily high tenure-track requirements, such discoveries become UNLIKELY.
A strong scientist is not defined by high “academic metrics”.
A strong scientist is the one who proposes risky creative endeavors outside the conventional boundaries.
Who sees risk as an opportunity to make discoveries.
And who is constantly seeking out these risks in the lab.
__
My new conversation with the leading expert in creativity research - Prof. Keith Sawyer - about discoveries, academia and professional myths:
youtu.be/HiDZfBJIBIw
___
monosov_lab retweeted
Online now: Advancing NeuroAI through developmental alignment dlvr.it/TTfbrh
monosov_lab retweeted
Now online! Whole-transcriptome-scale isoform-resolved spatial imaging of single cells in tissues dlvr.it/TTZGrw
monosov_lab retweeted
Online now: Sparse component analysis: A method that uncovers separable computations within neural population activity dlvr.it/TTKMlF
monosov_lab retweeted
🚨 Today in @NatureNano, we report a programmable way to synthesize mesoporous protein crystals inside living cells—turning cells into “reactors” for building spatially patterned, functional biomaterials.[1/n]
What has changed in mama bear brain (well, actually mice) to make her risk her life to attack a potential threat and protect her young? Oxytocin is the key! Happy to share our new study led by two awesome postdocs: Takashi Yamaguchi and Rongzhen Yan.
nature.com/articles/s41586-0…
monosov_lab retweeted
Most Dense Associative Memory models do this:
👉 1 hidden neuron activates 1 memory
That’s a bottleneck. Real-world data is compositional — thus our models should be too.
@mohi_shafiei designed a model that has this desired property! The configurations of visible neurons are encoded by combinatorial barcodes of activations in the hidden layer. The local minima of the energy (memories) become compositional — built from a set of core features encoded by individual hidden neurons.
And here’s the striking part:
👉 Memory capacity becomes exponential in the number of HIDDEN neurons. Not linear, as in previous models.
Check out our new #ICLR2026 paper: arxiv.org/abs/2601.00984. What would you build with this?
monosov_lab retweeted
We have developed a new AI-based assay to rapidly identify new molecular targets to inhibit cancer cell migration and metastasis.
See more details here: science.org/doi/10.1126/scia…
monosov_lab retweeted
🚨 Today in @Nature, we report GEMINI—a genetically encoded intracellular memory device that writes cellular dynamics into tree-ring-like fluorescent patterns within cytoplasmic protein assemblies.[1/n]
nature.com/articles/s41586-0…
monosov_lab retweeted
Congratulations to Olena, Andrew, and the rest of our incredible team! These exciting findings challenge neuron-centric models of fear - take a look!
nature.com/articles/s41586-0…
monosov_lab retweeted
Our paper is out! Really grateful to my colleagues, collaborators-experts in their respective field-, and my mentor Professor Ilya Monosov. @MonosovLab
cell.com/neuron/fulltext/S08…
! New paper from the lab !
How does novelty impact value-based decision making ?
What are the circuits and what mechanisms do they implement?
Congratulations to Dr. Takaya Ogasawara and team
cell.com/neuron/fulltext/S08…
monosov_lab retweeted
Interested in the latest advances in neuroscience (neural dynamics and internal models) and how they can be leveraged to build smarter, adaptive AI?
➡️ My first real solo piece 🖤🫶 @NatureNeuro
rdcu.be/eWVmA

































